Free Trial

Jason Mills Analyst Performance

Analyst at Canaccord Genuity Group

Jason Mills is a stock analyst at Canaccord Genuity Group in the medical sector, covering 14 publicly traded companies. Over the past year, Jason Mills has issued 2 stock ratings, including buy and hold recommendations. While full access to Jason Mills' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jason Mills' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
126 Last 11 Years
Buy Recommendations
84.00% 105 Buy Ratings
Companies Covered
14 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy84.0%105 ratings
Hold16.0%20 ratings
Sell0.0%0 ratings

Out of 125 total stock ratings issued by Jason Mills at Canaccord Genuity Group, the majority (84.0%) have been Buy recommendations, followed by 16.0% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
78.6% of companies on NASDAQ
11 companies
NYSE
21.4% of companies on NYSE
3 companies

Jason Mills, an analyst at Canaccord Genuity Group, currently covers 14 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
14 companies
100.0%

Jason Mills of Canaccord Genuity Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED INSTRUMENTS
8 companies
57.1%
MED PRODUCTS
3 companies
21.4%
MED/DENTAL - SUPP
2 companies
14.3%
MEDICAL INFO SYS
1 company
7.1%

Jason Mills' Ratings History at Canaccord Genuity Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Penumbra, Inc. stock logo
PEN
Penumbra
1/20/2026Downgrade$350.93$374.00Hold
Penumbra, Inc. stock logo
PEN
Penumbra
7/30/2025Set Price Target$227.26$350.00Buy
Penumbra, Inc. stock logo
PEN
Penumbra
2/19/2025Boost Price Target$299.18$340.00Buy